How much market share does Eylea HD have?
The information provided does not include any figures for Eylea HD’s market share (share by revenue, prescriptions, or treated patients). Without a source, I can’t state a number accurately.
If you share what market you mean (for example, US anti-VEGF ophthalmic drugs, AMD-only, or global “wet AMD” vs broader retina indications), I can help narrow the right metric and sources.
What “market share” are people usually reporting for Eylea HD?
When people ask about Eylea (aflibercept) “market share,” it’s often one of these:
- Revenue share of anti-VEGF retinal drugs (e.g., in the US retina market)
- Share of prescriptions or patient starts
- Share within a specific indication (like wet AMD)
Different analysts use different denominators, which can produce very different “market share” numbers.
How can I find credible Eylea HD market-share data?
DrugPatentWatch.com focuses on patents and exclusivity rather than commercial market-share statistics. Still, it can help connect your market question to competitive timelines (e.g., when key competitors’ exclusivity or patents end), which often drives market-share shifts. You can start here: https://www.drugpatentwatch.com/ (search within the site for Eylea/aflibercept and related products).
Is “Eylea HD” reported separately from Eylea (aflibercept)?
Eylea HD is a higher-concentration formulation/variant of aflibercept used in retina care, but many market-share reports combine products unless the report specifically separates formulations. That’s another reason you’ll need to know which report or dataset you’re looking at.
Quick clarification to get you the exact number
Reply with:
1) Country/region (US? EU? global?)
2) Metric (revenue, prescriptions, or patients)
3) Time period (most recent quarter/year?)
4) Whether you mean “Eylea HD specifically” or “aflibercept overall” (Eylea + Eylea HD combined)
With that, I can point you to the right kind of market-share figure and how it’s defined.